For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Access Helpful Resources

CareASSIST patient support program

CareASSIST Patient Support Program

Resources and support for your eligible patients.

LEARN MORE  
JEVTANA (cabazitaxel) patient guide downloadable pdf

JEVTANA Patient Guide

A booklet to provide your patients information on advanced prostate cancer and why you consider treatment with JEVTANA next.

DOWNLOAD  
Share videos featuring real JEVTANA (cabazitaxel) patient and caregiver experiences with your patients

Patient Video Stories

Real-life experiences can be informative for your patients, especially when considering or starting a new treatment. They can hear from people who have been treated with JEVTANA, as well as get tips from another caregiver.

WATCH VIDEOS  

Treatment Calendar downloadable PDF

Treatment Calendar

Keep track of treatments with a customizable calendar for each treatment cycle.

DOWNLOAD  
Side Effect Tracker downloadable PDF

Side Effect Tracker

Helps your patients keep track of side effects so you have a more complete picture of their treatment.

DOWNLOAD  
Medication Tracker downloadable PDF

Medication Tracker

A way for your patients to list and organize their medications and capture important information about taking each.

DOWNLOAD  
Test Results Tracker downloadable PDF

Test Results Tracker

Document test results, such as PSA levels, scans, etc.

DOWNLOAD  
Care Team Directory downloadable PDF

Care Team Directory

Record contact information for every care provider that patients depend on.

DOWNLOAD  

IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue 
Cancel